Data Insights

Ivonescimab by Akeso for Ovarian Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Ovarian Cancer

Data Insights

Ivonescimab by Summit Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Summit Therapeutics and currently in Phase III for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Non-Small Cell Lung Cancer

Data Insights

Ivonescimab by Summit Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Summit Therapeutics and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Squamous Non-Small Cell Lung Cancer

Data Insights

Ivonescimab by Akeso for Small-Cell Lung Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Small-Cell Lung Cancer

Data Insights

Ivonescimab by Akeso for Colorectal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Colorectal Cancer

Data Insights

Ivonescimab by Akeso for Cervical Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Cervical Cancer

Data Insights

Ivonescimab by Akeso for Gastric Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gastric Cancer

Data Insights

Ivonescimab by Akeso for Gallbladder Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gallbladder Cancer

Data Insights

Ivonescimab by Akeso for Fallopian Tube Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Fallopian Tube Cancer

Data Insights

Ivonescimab by Akeso for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Ivonescimab by Akeso for Hypopharyngeal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Hypopharyngeal Cancer

Data Insights

Ivonescimab by Akeso for Laryngeal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Laryngeal Cancer

Data Insights

Ivonescimab by Akeso for Oropharyngeal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Oropharyngeal Cancer

Data Insights

Ivonescimab by Akeso for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Ivonescimab by Akeso for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Extrahepatic Bile Duct Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Extrahepatic Bile Duct Cancer

Data Insights

Ivonescimab by Akeso for Metastatic Colorectal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Metastatic Colorectal Cancer

Data Insights

Ivonescimab by Akeso for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Oral Cavity (Mouth) Cancer

Data Insights

Ivonescimab by Akeso for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Ivonescimab by Akeso for Peritoneal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Peritoneal Cancer

Data Insights

Ivonescimab by Akeso for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Recurrent Head And Neck Squamous Cell Carcinoma